CA Patent

CA3172668A1 — Delayed release deferiprone tablets and methods of using the same

Assigned to Chiesi Farmaceutici SpA · Expires 2019-05-02 · 7y expired

What this patent protects

The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which …

USPTO Abstract

The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Drugs covered by this patent

Patent Metadata

Patent number
CA3172668A1
Jurisdiction
CA
Classification
—
Expires
2019-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Chiesi Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.